Recurrence of hepatitis B and delta hepatitis after orthotopic liver transplantation

M R Lucey, D M Graham, P Martin, A Di Bisceglie, S Rosenthal, J G Waggoner, R M Merion, D A Campbell, T T Nostrand, H D Appelman

Abstract
The clinical course of 10 liver transplant recipients who had hepatitis B virus (HBV) and five recipients with HBV and D (delta) infection before transplantation is described. Six patients who underwent eight transplants died. The estimated one and two year survival rates in patients with HBV only before transplantation were 74% and 67% respectively. The estimated one and two year survival rates in patients with HBV and HDV infection beforehand was 100%. Graft infection by HBV occurred in 8 of 10 patients infected with HBV only; and in 4 of 5 patients with previous HBV and HDV infection. There was a widely variable time from transplantation to the appearance of HBV markers in liver or serum, ranging from 6–331 days. Hepatitis D antigen (HDAg) appeared in three grafts very rapidly after transplantation at 4, 8, and 37 days respectively. Graft infection by HBV was accompanied by significant liver injury in six allografts in five recipients. In particular, there was a striking morphological appearance in five infected livers in which the hepatocytes became progressively enlarged and distorted as they accumulated huge amounts of hepatitis B surface and core antigens (HBsAg, HBeAg). These features were accompanied by pericellular fibrosis and cholestasis but little associated inflammation. This syndrome carried a poor prognosis. A gradual progression to cirrhosis occurred in one additional liver. Finally, recurrent HBV infection was a principal or a contributing factor in all deaths. The presence of HBeAg and inflammation in the native liver has increased the risk of HBV induced tissue damage in the graft whereas HDV infection in the host liver seemed to reduce the risk of significant HBV induced tissue damage in the allograft. These data suggest that post transplant HBV infection is accompanied by a variety of changes in the liver allograft, some of which are unique to the transplanted liver and may result in impaired allograft function.

(Put 1992; 33: 1390–1396)

While liver transplantation has become the treatment of choice in the developed world for many forms of serious acute and chronic liver diseases, its role in the management of liver disease caused by hepatitis B virus (HBV) and hepatitis D (or delta) virus (HDV) infection remains controversial. It has been observed that reinfection of the grafted liver by HBV either alone or with HDV is common. However, the nature and severity of the liver injury associated with graft reinfection is variable. In this report we review the sequence of changes in liver allografts performed in a series of HBV surface antigen (HBsAg) positive patients, and describe the clinical and pathological factors that seem to influence the course of recurrent HBV infection.

Patients and methods
We studied all patients with HBV infection who underwent orthotopic liver transplantation at the University of Michigan Medical Center between June 1987 and October 1989. These patients were monitored at frequent intervals (1–3 months) by physical examination, measurement of biochemical tests of liver integrity and function, and serological tests for HBV markers. Our operative and immunosuppressive approach has been described elsewhere. All patients were managed initially with Minnesota antilymphoblast globulin, methylprednisone, and azathioprine with maintenance triple drug therapy consisting of cyclosporin A, prednisone, and azathioprine. Acute cellular rejection was treated by short courses of high dose corticosteroids or OKT3. Liver biopsy specimens were taken whenever rejection was suspected clinically and according to a protocol — usually at 7, 14, and 21 days, 6 months, 1, and 2 years. One hundred and fourteen specimens were available for review, a median of 7 per patient.

Intravenous anti-HBs immunoglobulin Ig (HBIG, Abbott Laboratories) was administered intraoperatively (50–125 cc) in 11 transplants, and in four of these postoperatively (50–150 cc) also, according to a schedule of 10 cc per day. Six transplants were not given cover by HBIG. Serum aminotransferase activities and bilirubin concentrations were measured by autoanalyzer. Serum hepatitis B surface antigen was estimated by radioimmunoassay (AUSRIA II, Abbott, North Chicago, IL); hepatitis B e antigen (HBeAg) was assayed by enzyme linked immunosassay (HBeAg test, Abbott Laboratories, North Chicago, IL); and HD antibody (HBDAb) was estimated by ELISA (Abbott, North Chicago, IL). HBV DNA was estimated in serum by dot-blot hybridisation as previously described. The minimal level of detection of this assay is 0.1 pg HBV DNA per sample. Hepatitis C antibody (HCAb) was measured in stored sera using a radioimmunoassay kit (Ortho). Sections of formalin fixed native livers and liver allograft biopsy specimens were routinely stained with haematoxylin and eosin, trichrome, and periodic acid Schiff (PAS) with diastase. Immunohistochemical stains for HBCAg and HBsAg were performed using commercially available polyclonal antisera (Dako, Carpinteria, CA) and the avidin-biotin peroxidase complex technique.
Recurrence of hepatitis B and delta hepatitis after orthotopic liver transplantation

Table I: Fifteen patients with hepatitis B virus (HBV) infection undergoing orthotopic liver transplantation

<table>
<thead>
<tr>
<th>Gender (M:F)</th>
<th>13:2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median age (years) (range)</td>
<td>38 (14-64)</td>
</tr>
<tr>
<td>Median duration of disease (years) (range)</td>
<td>5 (0-1-13)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Source of hepatitis:</th>
<th>IVDA</th>
<th>Transfusion</th>
<th>Sexual contact</th>
<th>Unknown</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2</td>
<td>4</td>
<td>1</td>
<td>8</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Preoperative hepatitis markers:*</th>
<th>HBSAg</th>
<th>HBeAg</th>
<th>HBV-DNA</th>
<th>Anti-HD Ab</th>
<th>Anti-HC Ab</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liver biopsy/hepatectomy specimen:*</td>
<td>Cirrhosis</td>
<td>Massive necrosis</td>
<td>HBsAg</td>
<td>HbcAg</td>
<td>HDAd</td>
</tr>
<tr>
<td>15/15</td>
<td>8/15</td>
<td>2/11</td>
<td>1/15</td>
<td>13/15</td>
<td>9/15</td>
</tr>
<tr>
<td>10/12</td>
<td></td>
<td>4/14</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

IVDA = intravenous drug abuser
*Denominator indicates numbers tested.

HDAg was detected immunohistochemically using modified technique of Recchia et al. The parafin embedded specimens were first digested with proteinase K and subsequently coated with 1/100 dilution of anti-delta antibody positive human serum and then with a rabbit anti-human IgG (1/16 diluted, Dako, Accurate Chem). After this, the specimens were treated with diaminobencidine tetrahydrochloride-hydrogen peroxide mixture and haematoxylin staining was subsequently undertaken. Liver biopsy samples were read under code by two observers (DMG and HDA) except for HD antigen staining which was read under code by ADB and PM.

Results

The 15 patients studied are described in Table I. Chronic disease was present before transplant in 13, with a median known duration of HBsAg carriage of 48 months. Two patients presented with an acute syndrome, one of whom was HDV infected. Since the explanted liver of the latter patient was cirrhotic, it is likely that this represented acute, HDV induced decompensation preceded by clandestine chronic HBsAg carriage. The source of HBV infection was unknown in eight patients. The remainder had acquired HBV by intravenous drug use, transfused blood products (including one patient with haemophilia B previously reported), and presumed sexual contact. No patient had primary hepatocellular carcinoma.

The preoperative HBV and HBD serology and hepatocytology findings are summarised in Table I. All patients had HBsAg in serum, eight were HBeAg positive, and two were HBV DNA positive. HBeAg was shown immunohistochemically in the hepatocyte specimen from 13 patients; seven native livers were HBeAg positive as well. When these data were combined and the presence of at least one of the following (serum HBeAg, serum HBV DNA, liver HBeAg) taken to indicate viral replication, markers of viral replication were observed preoperatively in 13 of 15 patients. There was evidence of HDV infection in five patients, each of whom was positive for HDAb in serum and HDAg in liver.

Eight of the 10 patients with previous HBV infection alone developed serum HBsAg after transplantation. The median interval from transplantation to the presentation of serum HBsAg...
positive after transplant, became HBsAg positive irrespective of HDV infection. Five of 12 patients with HBV infected allografts developed progressive liver damage. Serial biopsy specimens of the liver allografts in four of these patients showed a sequence beginning with hepatocyte enlargement and indistinct changes leading to the formation of rigid hepatocyte cords aligned in parallel (Fig 1A). HBeAg was usually the first viral antigen to be detected by immunohistochemistry (Fig 1B). Next, the hepatocytes became considerably enlarged and contained the typical HBV type ground-glass inclusions. The inclusions were cytoplasmic, eccentric to and sometimes partly surrounding the nucleus, and were composed of finely granular pale material which seemed to retract from the cell membrane, leaving a partial clear zone between membrane and inclusion. Immunohistochemistry showed that these distorted hepatocytes stained intensely for cytoplasmic HBsAg and cytoplasmic and nuclear HBeAg (Fig 2A, B). Intraducellular and canalicul ar cholestasis, as well as peripoortal ductular proliferation always accompanied these cellular changes as the disease progressed. Despite the striking lobular disorganisation and prominent hepatocellular changes, there was only mild inflammation. Fibrosis was variable, ranging from subtle, thin peripoortal and perisinusoidal collagen fibres to diffuse peripoortal and panlobular pericellular fibrosis (Fig 3). In two cases there were foci of confluent lobular necrosis and haemorrhage, presumably because of superimposed ischaemia. All four patients who developed this sequence of biopsy changes died, including one patient in whom this pattern occurred in two allografts. The median interval from identification of fibrosing cholestatic hepatitis to death or transplantation was 53 days, range 35 to 85 days.

One additional patient with HBV alone before the transplant, rapidly developed HBV graft infection as shown by stainable HBsAg in a biopsy specimen taken only six days after transplantation. Another biopsy specimen taken 22 days later showed the 'rigid cord pattern' described above. This was followed by a non-inflammatory HBV carrier state at 27 weeks (Fig 4) and a mild persistent hepatitis 33 weeks after transplantation. Subsequent biopsy specimens taken at 19, 25, and 41 months showed a quiescent cirrhosis with HBeAg and HBsAg in scattered hepatocytes (Fig 5). He is currently alive 43 months after transplantation.

Seven patients with HBV infected allografts had a mild clinical disease. Five of these seven patients were also infected with HDV before transplantation, and recurrent HDV was documented in three. The mild clinical disease corresponded with either a persistent or smouldering lobular hepatitis or a non-inflammatory HBV carrier state. Serial biopsy specimens in these patients often showed variations in the intensity of inflammation and hepatocyte necrosis. There was no consistent pattern to the liver enzyme activities which corresponded to the appearance of HBsAg or HBV DNA in serum or HBsAg or HBeAg, or both, in liver. The reappearance of serum markers of HBV often occurred while

Figure 2: (A) Disorganised lobules contain appreciably swollen, distorted hepatocytes and scattered foci of necrosis. This biopsy specimen was obtained 15 months after transplant from a patient who died of liver failure and sepsis two months later. (Haematoxylin and eosin; original magnification ×200.) (B) Immunohistochemical stain for hepatitis B surface antigen shows diffuse cytoplasmic staining. (Original magnification ×200).
serum transaminases activities were at or near normal. However, two of the patients with HBV and HDV showed a distinct clinical hepatic syndrome about 12 weeks after transplantation. Malaise and appreciable increases in serum transaminase activities coincided with a marked increase in the number of hepatocytes staining for HDAg and also the first histological appearance of HBcAg (Fig 6). In one patient, this was accompanied by a histological pattern of acute viral hepatitis, whereas there was only an exacerbation of mid-lobeular hepatitis in the other. Both patients were given a course of OKT3. This was followed by a decline and then a second smaller peak in serum transaminase activities. Immunohistochemistry showed persistent HDAg and HBCAg within hepatocytes. This rebound hepatitis resolved to a plateau of moderately abnormal transaminase activities and histological features of chronic persistent hepatitis and continued staining of hepatocytes for HBsAg, HBCAg, and HDAg without further adjustments in immunosuppression.

Three patients originally infected with HBV alone did not develop serological or biopsy evidence of HBV graft infection at 8, 16, and 17 months after transplantation, respectively. One of these patients, whose postoperative course was complicated by systemic cytomegalovirus infection, developed smoldering lobular hepatitis seen in biopsy specimens obtained 45, 125, 229, and 240 days after transplant. Progressive cholestasis accompanied the hepatitis in the final two biopsy specimens. Testing for serum anti-HCV was not performed. The patient died of liver and pulmonary failure caused by cytomegalovirus and aspergillosis on day 242. Another patient developed a persistent hepatitis of unknown aetiology at six months followed by a normal biopsy specimen at 15 months. The third patient has declined a liver biopsy since day 68 after transplant, at which time the graft showed lobular disorganisation without inflammation.

Patients were stratified according to whether recurrent HBV caused severe, progressive liver injury, including cirrhosis, or mild liver disease (see Table III). Progressive disease was more common in older recipients and among patients with active inflammation and HBCAg in their native livers. Progressive disease did not occur in the infected allograft when the corresponding native livers showed quiescent cirrhosis or massive necrosis. Coinfection of the allograft by HBV and HDV was always associated with a mild disease and prolonged survival. Eight of 10 patients who received HBIG and 5 of 6 who did not receive HBIG developed serological markers of active HBV infection. The median duration to the development of HBV markers in serum or liver was 78 days (range 14–331) in patients receiving HBIG compared with 39 days (range 6–219) in those who did not receive HBIG. The median time to detection of HBV infection was 33 days (range 6–224) in the five patients who received six grafts which developed progressive liver injury (fibrosing cholestatic hepatitis or cirrhosis) compared with 39 days (range 26–331) in seven patients with recurrent HBV associated with mild liver disease.

Sera taken before and after transplantation have been tested retrospectively for anti-HC Ab in 12 patients. Ten were positive preoperatively and eight postoperatively. Neither patient who was negative before transplantation developed anti-HC Ab after transplantation.

Discussion
This study describes the clinical events that occur when HBV, with or without HDV, infects the transplanted liver. Starzl et al reported on liver transplantation in 52 adult patients with HBV infection in whom the 24 month survival was 50% compared with 76% in 744 adult liver recipients with non-malignant disease. These and other authors have found that recurrence of
HBV in the grafted liver is very frequent. Our experience in a smaller series is almost identical, in that HBV infection occurred in 13 of 16 grafts and death occurred in 5 of 10 patients whose grafts were infected with HBV alone.

Our data show that recurrent HBV infection is accompanied by a variety of disease patterns in the transplanted liver. One form, which seems unique to the infected allograft, was seen in four of our patients. Severe rapidly progressive liver disease was associated with the following histopathological features: distorted ground glass hepatocytes laden with HBsAg and HbcAg, cholestasis, a variable degree of fibrosis, and in some cases, lobular necrosis. This pattern is indistinguishable from 'fibrosing cholestatic hepatitis' described by Davies et al., and like them we found it to portend a bad prognosis. The Pittsburgh group also described a similar constellation of findings and noted that HBV infection seems to progress more rapidly when it recurs in a second allograft. This was also our experience in one patient in whom 'fibrosing cholestatic hepatitis' was seen in the first transplant at 20 weeks after progressed to require retransplantation at 32 weeks. Thereafter, a similar histological pattern evolved rapidly in the second allograft from which biopsy specimens were taken at 14, 26, and 32 days. This patient died of liver failure 2.1 months after the second operation.

We observed a gradual progression to cirrhosis in one HBV infected allograft. The initial biopsy specimens in that patient also passed through the stages seen in our allografts which eventually developed 'fibrosing cholestatic hepatitis'—namely hepatocytes in rigid cords and later distorted ground glass hepatocytes. It is unclear what factors dictate whether an infected liver in which there are early signs of tissue injury will progress to 'fibrosing cholestatic hepatitis' or cirrhosis. The progression to cirrhosis in our patient occurred despite the lack of significant inflammation.

In contrast, many allografts became infected with HBV without developing significant tissue injury. A benign clinical course was associated with: absence of immunoreactive HbcAg or active cirrhosis in the native liver, as well as the presence of HDAg in the native liver. These data suggest that the risk of liver damage is greatest in patients with active viral replication before operation. HDV may be protective by suppressing HBV replication in the native liver and the transplanted liver. Furthermore, we observed a curious biphasic hepatitis beginning approximately 12 weeks after transplantation in two patients coinfected with HBV and HDV which resolved to stable chronic persistent hepatitis. This acute syndrome coincided with a surge in expression of both HBV and HDV proteins. One explanation of this phenomenon is that there was an increase in HDV expression which then suppressed HBV expression allowing a stable equilibrium to develop between the two viruses and the liver.

Our data do not allow us determine whether HBIG is beneficial in preventing or ameliorating recurrent HBV. However, recent evidence suggests that HBIG may reduce the frequency, or extend the time to onset, of recurrent HBV. Indeed Samuel et al reported that when HBIG was administered on a regular basis in the first two years after liver transplantation to 110 patients who had been serum HBsAg positive, HBsAg reappeared in 22.7% only. However, since the reappearance rate was much higher (96%) in patients with evidence of active viral replication (serum HBV DNA positive), and since our data would suggest that the severity of injury in the infected allograft is also dependent on the HBV status of the native liver, the efficacy of repeated administration of HBIG deserves to be tested within a randomized controlled study.

The frequent recurrence of HBV and HDV in liver allografts raises interesting questions about the source of HBV and HDV. We presume that those patients who manifested HBV in the allograft within days of transplantation acquired it from virus shed into the blood stream before or during the operation. Similarly, the very short time taken for HDAg to appear in three grafts suggests it was spread peroperatively. However, in some patients there was a considerable delay before markers for HBV infection were found. This may be a phenomenon of test sensitivity in which infection of the graft occurred peroperatively in these patients also. However, in a series of HBsAg positive patients undergoing liver transplantation Feray et al found HBV-DNA genome sequences in peripheral blood mononuclear cells in 7 of 11 liver transplant recipients who were serum HBsAg negative and liver HBV-DNA negative by polymerase chain reaction postoperatively. Extrahepatic HBV-DNA sequences have been observed in human autopsy specimens including lymph nodes, spleen, kidney, pancreas, brain, and endocrine tissues. Thus, HBV infected extrahepatic tissues, including peripheral blood mononuclear cells,
Recurrence of hepatitis B and delta hepatitis after orthotopic liver transplantation

 Liver
 Cirrhosis + - - - -
 GGH + - - - -
 Rejection - + - - -
 HDAg + + + + + + + +
 HBSAg + + + + + + + +
 HBCAg - - - - - - - -
 Serum
 HBSAg + - - - +
 HBeAg - + - - -
 HBV DNA +
 OKT3 +

 Figure 6: Clinical sequence in a patient with hepatitis B and D virus infection demonstrating coincidence of acute inflammatory pattern of liver enzymes with increased expression of hepatitis B and hepatitis D viral proteins within the grafted liver. Week 0 on the abscissa indicates the time of liver transplantation. GGH refers to large ground glass hepatocytes. OKT3 indicates a 10 day course of orthoclone OKT3 (see text).

 may be important potential sources for late infection of the graft.

 The evidence that HBV infection can cause severe liver damage in liver transplant recipients who are immunosuppressed suggests that cellular immunity may not be the sole mechanism for HBV associated liver injury and agrees with data on HBV infections in other immunosuppressed states.17,18 A common feature that we observed in HBV infected liver transplants was an abundance of distorted ground glass hepatocytes. These contain HBSAg and both nuclear and cytoplasmic HBCAg, signifying intense viral replication.19 One explanation for this unbridled production of HBV proteins is that it is fostered by concurrent medications, including glucocorticoids and cyclosporin. Tur-Kaspa et al have identified a glucocorticoid responsive expression enhanced element in the HBV genome.20 The effect of cyclosporin on HBV has not been studied, although it is interesting that when cyclosporin was administered to woodchucks who were infected with a related hepadnavirus, it resulted in a significantly more severe hepatitis and sustained viraemia than in non-cyclosporin treated controls.21 The increased expression of HBV proteins, especially pre S1 proteins, in the present patients probably perturbs the process whereby HBSAg is secreted by the infected hepatocyte.22 A comparable phenomenon has been described in a transgenic mouse model which produces long segments of HBSAg including pre S1 proteins and which eventually develops distorted ground glass hepatocytes very similar to those in the present liver transplant recipients.23 It is uncertain whether the development of these ground glass hepatocytes is a benign phenomenon or is linked with the progression to liver damage. In the transgenic mouse model, hepatocellular damage, including multinodular regenerative hyperplasia, raised transaminase activities and eventual tumour formation have been described. It is of interest, therefore, that de novo development of a hepato- toma has been reported in a liver allograft infected with HBV.24

 The authors thank Mrs Muriel Fritz for assistance in preparing this manuscript. This work was presented in part to the digestive disease week of the American Gastroenterological Association, May 1989, and published in abstract: Gastroenterology 1989; 96: A624.

<table>
<thead>
<tr>
<th>HBV in allograft</th>
<th>Age at transplant (years)</th>
<th>Histopathology of native liver</th>
<th>HBSAg in native liver</th>
<th>HDAg in native liver</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reinfected, mild disease</td>
<td>7 32</td>
<td>Active cirrhosis</td>
<td>1</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Quiescent cirrhosis</td>
<td>4</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Massive necrosis</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>Reinfected, severe disease</td>
<td>5 48</td>
<td>Active cirrhosis</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Quiescent cirrhosis</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>No evidence of reinfection</td>
<td>3 47</td>
<td>Active cirrhosis</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>


Recurrence of hepatitis B and delta hepatitis after orthotopic liver transplantation.

M R Lucey, D M Graham, P Martin, A Di Bisceglie, S Rosenthal, J G Waggoner, R M Merion, D A Campbell, T T Nostrant and H D Appelman

Gut 1992 33: 1390-1396
doi: 10.1136/gut.33.10.1390

Updated information and services can be found at:
http://gut.bmj.com/content/33/10/1390

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections

Articles on similar topics can be found in the following collections

Hepatitis other (155)
Pancreas and biliary tract (1949)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/